2Gupta S, Leatham EW, Carrington D, et al. Elevated chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of acute myocardial infarction [ J ]. Circulation, 1997,96(2) :404 -407.
3Gurfinkel E , Bozovich G, Beck E , et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary, syndromes. The final report of t he ROXIS Study [ J]. Eur Heart J, 1999,20(2) :121 - 127.
4OConnor CM, Dunne MW, Pfeffer MA, et al. Azithrornycin for the secondary prevention of coronary heart disease events: the WIZARD Study: a randomized controlled trial[ J]. JAMA ,2003,290 : 1459.
5Grayston J T, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events [ J ]. N Engl J Med,2005, 352 (16) :1637 -1645.
6Cannon CP, Braunwald E, McCabe CH, et al. Antibiotict treatment of chlamydia pneumoniae after acute coronary syndrome [ J]. N Engl J Med ,2005, 352 (16) : 1646 - 1654.
2Lutgens E, Daemen MJ. CD40 -CD40L interactions in atherosclerosis [ J ]. Trends Cardiovasc Med,2002,12 ( 1 ) :27 - 32.
3Kari O, Turid MP, Nils OS. Release of soluble CD40-ligand after platelet activation: Studies on the solubilization phase[ J ]. Thrombosis Research ,2004,114(3 ) : 167 - 177.
4Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40-ligand in acute coronary syndromes [ J ]. N Engl J Med, 2003,348 ( 12 ) : 1104-1111.
8Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndromes[J]. Am Heart,2001,141(2) :211 -217.
